Show simple item record

dc.contributor.authorTurner, NCen_US
dc.contributor.authorLiu, Yen_US
dc.contributor.authorZhu, Zen_US
dc.contributor.authorLoi, Sen_US
dc.contributor.authorColleoni, Men_US
dc.contributor.authorLoibl, Sen_US
dc.contributor.authorDeMichele, Aen_US
dc.contributor.authorHarbeck, Nen_US
dc.contributor.authorAndré, Fen_US
dc.contributor.authorBayar, MAen_US
dc.contributor.authorMichiels, Sen_US
dc.contributor.authorZhang, Zen_US
dc.contributor.authorGiorgetti, Cen_US
dc.contributor.authorArnedos, Men_US
dc.contributor.authorHuang Bartlett, Cen_US
dc.contributor.authorCristofanilli, Men_US
dc.coverage.spatialUnited Statesen_US
dc.identifier.citationJ Clin Oncol, 2019, 37 (14), pp. 1169 - 1178en_US
dc.description.abstractPURPOSE: A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. METHODS: The PALOMA-3 ( identifier: NCT01942135) trial randomly assigned 521 endocrine-pretreated patients with metastatic breast cancer to receive palbociclib plus fulvestrant or placebo plus fulvestrant. Primary analysis was first conducted on 10 genes on the basis of pathway biology and evidence from previous studies followed by a systematic panel-wide search among 2,534 cancer-related genes. The association of gene expression with the effect of palbociclib on progression-free survival (PFS) was evaluated using Cox proportional hazards regression analysis, with gene expression as a continuous variable or dichotomized by median. An independent breast cancer cohort from the Preoperative Palbociclib (POP) Clinical Trial ( identifier: NCT02008734) was used for validation, in 61 patients with primary breast cancer treated with 2 weeks of palbociclib. RESULTS: In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients). Palbociclib efficacy was lower in patients with high versus low cyclin E1 (CCNE1) mRNA expression (median PFS: palbociclib arm, 7.6 v 14.1 months; placebo arm, 4.0 v 4.8 months, respectively; interaction P unadjusted = .00238; false discovery rate-adjusted P = .0238). CCNE1 mRNA was more predictive in metastatic than in archival primary biopsy tissue samples. No significant interaction was found between treatment and expression levels of CDK4, CDK6, cyclin D1, and RB1. Palbociclib was efficacious in both luminal A and luminal B tumors. High CCNE1 mRNA expression was associated with poor antiproliferative activity of palbociclib in the POP trial (P = .005). CONCLUSION: Addition of palbociclib to fulvestrant demonstrated efficacy in all biomarker groups, although high CCNE1 mRNA expression was associated with relative resistance to palbociclib.en_US
dc.format.extent1169 - 1178en_US
dc.titleCyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.en_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJ Clin Oncolen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Oncologyen_US
dc.contributor.icrauthorTurner, Nicholasen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as